<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435848</url>
  </required_header>
  <id_info>
    <org_study_id>BST002</org_study_id>
    <nct_id>NCT03435848</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy</brief_title>
  <acronym>ELPIS</acronym>
  <official_title>A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioSight Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioSight Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assesses the benefit, safety, and pharmacokinetics (PK) of&#xD;
      BST-236 in patients with newly-diagnosed Acute Myeloid Leukemia (AML) who are not eligible&#xD;
      for standard induction chemotherapy due to advanced age or comorbidities. The Complete&#xD;
      Remission (CR) rate following treatment with BST-236 will be compared to the CR rate reported&#xD;
      in historical data in a similar population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BST-236 is a cytarabine pro drug designed to release cytarabine inside the target cells with&#xD;
      reduced systemic exposure to free cytarabine. As such, BST-236 may enable delivery of high&#xD;
      doses of cytarabine to medically-unfit or older adults who otherwise cannot be treated with&#xD;
      standard cytarabine therapy. This study aims to validate this hypothesis.&#xD;
&#xD;
      The study is an open-label, single arm, single agent, multi-center study in adults with newly&#xD;
      diagnosed AML who are unfit for standard therapy. The patients will receive up to 4 courses&#xD;
      of six-days treatment with intravenous BST-236; 1 or 2 induction courses followed by 1 to 2&#xD;
      consolidation courses. The study participation will be 52 weeks including treatment and&#xD;
      follow-up periods. An additional 1 year post study follow-up for the evaluation of survival&#xD;
      is optional.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>Day 28-35 of induction/re induction course</time_frame>
    <description>as BM blasts &lt;5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC &gt;1.0x 109/L (1,000/μL); platelet count &gt;100 x 109/L (100,000/μL)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>BST-236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BST-236</intervention_name>
    <description>1 to 4 courses</description>
    <arm_group_label>BST-236</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult ≥18 years of age&#xD;
&#xD;
          2. AML according to the 2016 revision to the World Health Organization (WHO)&#xD;
             classification of myeloid neoplasms and acute leukemia: ≥20% blasts in peripheral&#xD;
             blood or marrow&#xD;
&#xD;
               1. de-novo AML or&#xD;
&#xD;
               2. AML secondary to MDS or&#xD;
&#xD;
               3. AML secondary to exposure to potentially leukemogenic therapies or agents (e.g.&#xD;
                  radiation therapy, alkylating agents, topoisomerase II inhibitors) with the&#xD;
                  primary malignancy in remission for at least 2 years&#xD;
&#xD;
          3. Not eligible for standard induction chemotherapy;&#xD;
&#xD;
               1. Age ≥75 years or&#xD;
&#xD;
               2. Age ≥18 years with at least one of the following comorbidities:&#xD;
&#xD;
             i. Clinically significant heart or lung comorbidities, as reflected by at least one&#xD;
             of:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) ≤50%&#xD;
&#xD;
               -  Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected&#xD;
&#xD;
               -  Forced expiratory volume in 1 second (FEV1) ≤65% of expected ii. Chronic stable&#xD;
                  angina or congestive heart failure controlled with medication iii. Other&#xD;
                  contraindication(s) to anthracycline therapy (must be documented) iv. Other&#xD;
                  comorbidity that the Investigator judges as incompatible with intensive remission&#xD;
                  induction chemotherapy, which must be documented&#xD;
&#xD;
          4. Creatinine clearance (estimated by the Cockroft-Gault (C-G) or measured by 24 hours&#xD;
             urine collection) ≥45 mL/min&#xD;
&#xD;
          5. Liver enzymes (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)&#xD;
             ≤2.5 times the upper limits of normal (ULN)&#xD;
&#xD;
          6. Total bilirubin ≤1.5 x ULN unless due to known history of Gilbert's disease&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at screening&#xD;
&#xD;
          8. Prepared and able to give written (signed and dated) informed consent, which includes&#xD;
             compliance with study requirements and restrictions prior to admission to the study&#xD;
&#xD;
          9. Women of reproductive potential must have a negative serum pregnancy test within 48&#xD;
             hours of the first day of any BST-236 treatment course&#xD;
&#xD;
         10. Women or men of reproductive potential must use (or have his/her partner use) two&#xD;
             forms of effective birth control methods starting from 1 month prior to screening and&#xD;
             until 3 months following the last BST-236 administration day (acceptable methods of&#xD;
             birth control in this study include: surgical sterilization, intrauterine devices,&#xD;
             oral contraceptives, contraceptive patch, long-acting injectable contraceptives,&#xD;
             partner's vasectomy, or double-barrier method condom or diaphragm with spermicide)&#xD;
&#xD;
         11. Patient must voluntarily sign and date an ICF, approved by an Independent Ethics&#xD;
             Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any&#xD;
             screening or study-specific procedures&#xD;
&#xD;
         12. Patient must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has relapsed or refractory AML&#xD;
&#xD;
          2. Patient has acute promyelocytic leukemia&#xD;
&#xD;
          3. Any previous treatment for AML (except for hydroxyurea or up to one treatment course&#xD;
             with hypomethylating agents (HMA))&#xD;
&#xD;
          4. Patient has history of myeloproliferative neoplasm (MPN) including myelofibrosis,&#xD;
             essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or&#xD;
             without BCR-ABL1 translocation and AML with BCR-ABL1 translocation&#xD;
&#xD;
          5. Previous use (prior to study initiation) of drugs containing cytarabine as an active&#xD;
             ingredient&#xD;
&#xD;
          6. Use of any HMA for the treatment of MDS within 30 days of study Day 1&#xD;
&#xD;
          7. Participation in a previous clinical trial and/or use of an investigational drug&#xD;
             within 90 days or at least 5 half-lives of tested drug (whichever is longer) of&#xD;
             initial screening assessment&#xD;
&#xD;
          8. Peripheral White Blood Cell (WBC) count &gt;30,000 /µL in the 48 hours prior to first&#xD;
             BST-236 dose administration. Hydroxyurea administration or leukapheresis is permitted&#xD;
             to meet this criterion&#xD;
&#xD;
          9. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing&#xD;
             signs/symptoms related to the infection without improvement despite appropriate&#xD;
             antibiotics or other treatment)&#xD;
&#xD;
         10. Any medical or surgical condition, presence of laboratory abnormalities or psychiatric&#xD;
             illness that may preclude safe and complete study participation based on the&#xD;
             Investigator's judgment&#xD;
&#xD;
         11. Diagnosis of malignant disease within the previous 12 months (excluding basal cell&#xD;
             carcinoma of the skin without complications, &quot;in-situ&quot; carcinoma, or other local&#xD;
             malignancy excised or irradiated with a high probability of cure and not treated with&#xD;
             chemotherapy)&#xD;
&#xD;
         12. Active malignant disease other than AML&#xD;
&#xD;
         13. Leptomeningeal/central nervous system involvement of AML&#xD;
&#xD;
         14. Myeloid sarcoma as a sole manifestation of AML&#xD;
&#xD;
         15. Surgical procedure, excluding central venous catheter placement or other minor&#xD;
             procedures (e.g. skin biopsy) in the 14 days prior to BST-236 administration&#xD;
&#xD;
         16. Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA)&#xD;
             class 4 congestive heart failure&#xD;
&#xD;
         17. Shortness of breath requiring continuous oxygen treatment for at least 15 hours per&#xD;
             day in chronically hypoxemic patients&#xD;
&#xD;
         18. History of allergic reactions attributed to compounds of similar chemical composition&#xD;
             as BST-236 and/or cytarabine&#xD;
&#xD;
         19. Life expectancy shorter than 3 months attributed to any known medical condition other&#xD;
             than AML&#xD;
&#xD;
         20. Active/chronic Hepatitis B Virus (HBV) infection (based on positive surface antigen&#xD;
             (HBsAg)), Hepatitis C Virus (HCV) infection (HCV) (based on positive HCV antibody&#xD;
             (Ab)), or Human Immunodeficiency Virus (HIV)-1 or HIV-2 (based on positive HIV&#xD;
             antibody)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Augusta University Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Physician Network Oncology and Hematology Specialists</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute Dallas Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-4433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>PO Box 151</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam medical center hematology department</name>
      <address>
        <city>Haifa</city>
        <zip>4655202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>P.O.B 3235</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Unfit for standard induction therapy</keyword>
  <keyword>Cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

